ClinicalTrials.gg
CompletedNCT07562204Updated May 1, 2026

Rapid Identification of Microbial Pathogens in Intra-abdominal Infections Using Multiplex PCR

An observational study in Intra Abdominal Infections and Peritonitis Infectious, sponsored by University of Göttingen. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Göttingen · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

With this study, the investigators want to determine whether a fast identification of microorganisms causing intra-abdominal infections in patients with suspected hollow organ perforation or peritonitis is possible using a multiplex PCR system (Unyvero A50), a method that allows rapid detection of predefined bacterial and fungal targets directly from clinical samples. Therefore, intra-abdominal peritoneal fluid samples collected during surgery will be analyzed by multiplex PCR and by conventional microbiological culture. The investigators want to determine whether multiplex PCR diagnostics could provide results faster than conventional microbiological methods and deliver additional information on pathogen detection.

Read the detailed description

This prospective observational study evaluates a rapid multiplex PCR system (Unyvero A50, Curetis) as an adjunct to conventional microbiological culture (cMB) in adult patients undergoing surgery for suspected hollow viscus perforation or peritonitis. During surgery, two intra-abdominal peritoneal fluid samples will be collected. One sample will be processed by routine aerobic and anaerobic culture at the microbiology laboratory. The second sample will be analyzed postoperatively using multiplex PCR at the surgical intensive care unit according to the manufacturer's instructions.

The study will compare turnaround time and concordance of pathogen detection between multiplex PCR and cMB. Additional descriptive analyses will include pathogen group distributions, polymicrobial findings, and results by anatomical site of perforation. Resistance markers detected by PCR will be recorded descriptively. Invalid PCR results will be documented and excluded from paired analyses.

02

Conditions studied

  • Intra Abdominal Infections
  • Peritonitis Infectious

Keywords

  • multiplex pcr
  • microbiological investigation
  • intra-abdominal infection
03

In context

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

This study's enrollment of 50 is below the median of 174 across 48 observational studies indexed under Intraabdominal Infections.

Browse Intraabdominal Infections studies →

Lead sponsor

University of Göttingen is the lead sponsor of 37 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with suspected hollow organ perforation at the University Medical Center Göttingen, who underwent surgical treatment and were admitted to the intensive care unit for postoperative care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • suspected hollow organ perforation
  • suspected peritonitis
  • patient underwent surgical treatment
  • microbiological testing of intra-abdominal fluid was needed

Exclusion criteria

Exclusion Criteria:

  • patient in moribund conditions
  • patient already enrolled in an interventional clinical trial
  • patient under 18
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Time to availability of multiplex PCR result (in days)

    Time from intraoperative peritoneal fluid sampling to availability of the multiplex PCR result (reported in days)

    Time frame: Up to 1 day post-sampling

  2. Time to availability of conventional microbiological culture result (in days)

    Time from intraoperative peritoneal fluid sampling to availability of the final conventional microbiological culture report (reported in days)

    Time frame: Up to 7 days post-sampling

Secondary outcomes

  1. Concordance of pathogen detection between multiplex PCR and conventional culture

    Proportion of evaluable sample pairs with complete concordance of pathogen detection between multiplex PCR and conventional microbiological culture

    Time frame: Perioperative (up to 7 days post-sampling)

07

Study locations

1 site
  • University Medical Center Göttingen
    Göttingen, 37075, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jun 2020, 24 months.

Of 24 observational studies under Intraabdominal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2026
First posted
May 1, 2026
StartActual
Jun 1, 2018
Primary completionActual
Jun 1, 2020
CompletionActual
Dec 31, 2020
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07562204
Lead sponsor
University of Göttingen
Responsible party
Dr. T. Perl (Principal Investigator, University of Göttingen) — Principal investigator
First posted
May 1, 2026
Start date
Jun 1, 2018
Primary completion
Jun 1, 2020
Completion
Dec 31, 2020
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion